 |
BioWorld-Insight-2002-09-09
Stock Winners and Losers For The Week
As Clock Ticks For Avastin Data, Genentech Faces Filing Decision
The climate may cool with September's advent, but the industry late last week was still expecting a blast of potentially hot autumnal news about Phase III trials of Genentech Inc.'s monoclonal antibody Avastin (bevacizumab) in combination with chemotherapy against breast cancer. (Bioworld Financial Watch)